Comparative Pharmacology
Head-to-head clinical analysis: EVALOSE versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVALOSE versus LORATADINE REDIDOSE.
EVALOSE vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine